enzym
one
import
class
drug
target
smallmolecul
enzym
inhibitor
transform
human
medicin
estim
compris
roughli
onethird
half
market
drug
sinc
import
bioactiv
lipid
recogn
great
attent
devot
enzym
involv
lipid
metabol
phospholipas
pla
superfamili
enzym
character
abil
hydrolyz
ester
bond
posit
membran
glycerophospholipid
releas
free
fatti
acid
includ
arachidon
acid
aa
initi
eicosanoid
cascad
matter
fact
pla
upstream
regul
eicosanoid
cascad
suppli
free
fatti
acid
cyclooxygenas
lipoxygenas
cytochrom
enzym
thu
produc
variou
inflammatori
mediat
includ
prostaglandin
leukotrien
thromboxan
involv
develop
progress
numer
inflammatori
diseas
pla
attract
great
interest
medicin
target
twenti
year
consequ
mani
smallmolecul
synthet
inhibitor
develop
academia
pharmaceut
compani
mammal
phospholipas
superfamili
consist
six
type
divers
enzym
giv
pla
cytosol
calciumdepend
pla
cpla
gvi
pla
calciumindepend
pla
ipla
sever
group
secret
pla
spla
two
group
plateletactiv
factoracetylhydrolas
pla
pafah
gvii
gviii
pla
gxv
pla
lysosom
pla
gxvi
pla
adipos
pla
howev
four
type
human
pla
target
develop
synthet
inhibitor
new
medicin
agent
giva
cpla
spla
claim
relat
compound
antiinflammatori
agent
act
inhibit
giva
cpla
aa
releas
fig
known
also
potent
inhibitor
giva
cpla
x
valu
mol
fraction
mix
micel
assay
ic
nm
vesicl
assay
found
suppress
releas
aa
ic
valu
fibroblastlik
synoviocyt
inhibitor
exhibit
vivo
antiinflammatori
effect
compar
refer
drug
methotrex
enbrel
prophylact
therapeut
collageninduc
arthriti
model
respect
recent
antiangiogen
effect
inhibitor
patientderiv
tripleneg
basallik
breast
cancer
model
evalu
signific
tumor
growth
inhibit
observ
day
treatment
decreas
endotheli
cell
prolifer
fewer
immatur
vessel
treat
tumor
shown
histolog
asubio
pharma
develop
anoth
indolebas
giva
cpla
inhibitor
fig
compound
found
potent
giva
cpla
inhibitor
via
enzym
assay
cellbas
assay
guinea
pig
human
wholeblood
assay
ic
valu
human
whole
blood
assay
daili
administr
markedli
amelior
liver
injuri
hepat
fibrosi
follow
week
treatment
ccl
indic
giva
cpla
inhibitor
could
use
treatment
nonalcohol
fatti
liver
diseas
includ
fatti
liver
hepat
fibrosi
anoth
import
class
giva
cpla
inhibitor
pyrrolidinebas
compound
pyrrophenon
fig
fig
class
inhibitor
pyrrolidin
framework
develop
seno
et
al
shionogi
inhibitor
commerci
avail
use
tool
understand
role
enzym
exhibit
ic
valu
nm
pcdog
assay
pyrrophenon
found
potent
revers
inhibitor
human
giva
cpla
ic
nm
strongli
inhibit
aa
releas
prostaglandin
e
pge
thromboxan
b
txb
leukotrien
b
ltb
format
human
whole
blood
combin
extens
molecular
dynam
md
simul
deuterium
exchang
mass
spectrometri
experiment
result
develop
tool
defin
accur
bind
site
follow
methodolog
demonstr
pyrrophenon
bound
enzym
numer
hydrophob
residu
locat
distal
activ
site
precis
bound
cap
region
near
interfaci
bind
surfac
enzym
recent
report
pyrrophenon
block
calcium
releas
endoplasm
reticulum
er
concomit
increas
mitochondri
calcium
respons
stimul
atp
serum
offtarget
effect
implic
serin
hydrolas
regul
er
calcium
releas
highlight
import
care
doserespons
studi
pyrrophenon
studi
giva
cpla
function
role
giva
cpla
local
system
diseas
pneumonia
infect
investig
demonstr
pharmacolog
inhibit
giva
cpla
block
streptococcu
pneumoniaeinduc
polymorphonuclear
cell
transepitheli
migrat
vitro
result
suggest
enzym
play
crucial
role
elicit
pulmonari
inflamm
pneumococc
infect
giva
cpla
shown
increas
mediat
variou
activ
sever
human
cancer
includ
colon
prostat
lung
cancer
recent
express
level
enzym
breast
cancer
cell
absenc
presenc
doxorubicin
patient
chemotherapi
studi
found
blockag
giva
cpla
either
pyrrophenon
sensit
aggress
breast
cancer
doxorubicin
suppress
extracellular
signalregul
kinas
erk
mammalian
target
rapamycin
mtor
kinas
thu
inhibit
giva
cpla
may
therapeut
valu
overcom
chemoresist
breast
cancer
recent
result
shown
giva
cpla
upregul
protein
express
induc
either
lipopolysaccharid
lp
interferon
gamma
effect
mediat
via
activ
oxidas
reduct
enzym
upregul
specif
antisens
inhibit
pyrrophenon
prevent
induct
protein
express
either
lp
result
suggest
giva
cpla
direct
role
upregul
featur
proinflammatori
indic
giva
cpla
may
serv
pivot
amplifi
inflammatori
respons
cn
anoth
studi
provid
evid
giva
cpla
activ
critic
involv
replic
variou
rna
viru
famili
may
thu
repres
candid
target
broadspectrum
antivir
drug
develop
inhibit
giva
cpla
activ
lowmolecularweight
inhibitor
profound
effect
viral
rna
protein
accumul
human
coronaviru
cell
lehr
cowork
develop
like
compound
fig
potent
inhibitor
giva
cpla
recent
work
studi
detail
structur
relat
compound
dual
inhibitor
giva
cpla
fatti
acid
amid
hydrolas
faah
bioisoster
replac
carboxyl
acid
function
invers
amid
sulfonylamid
carbam
urea
show
carboxyl
acid
function
lead
compound
special
import
pronounc
inhibit
giva
cpla
faah
sinc
serin
reactiv
keton
function
compound
readili
metabol
inact
alcohol
deriv
moieti
replac
cyanamid
nitril
serin
trap
effort
obtain
metabol
stabl
inhibitor
howev
studi
inhibitori
activ
metabol
stabil
substanc
reveal
case
increas
metabol
stabil
accompani
loss
inhibitori
potenc
giva
cpla
faah
structureact
relationship
studi
acid
explor
effect
butanoyl
hexanoyl
substitu
posit
indol
scaffold
bear
termin
group
vari
polar
inhibitori
potenc
consider
affect
case
metabol
phase
phase
ii
vitro
stabil
aqueou
solubl
influenc
modul
structur
modif
perform
sinc
giva
cpla
play
critic
role
neurodegen
disord
associ
neuroinflamm
effect
positron
emiss
tomographi
pet
radioligand
imag
giva
cpla
live
brain
might
prove
use
tool
biomed
research
thu
four
highaffin
acidbas
inhibitor
giva
cpla
ic
nm
select
label
carboxyl
posit
min
provid
candid
pet
radioligand
imag
brain
enzym
howev
synthes
test
c
arylcarboxyl
acid
show
low
brain
penetr
lack
retent
mous
brain
vivo
show
compound
ineffect
brain
pet
radioligand
giva
cpla
better
effici
ideal
giva
cpla
inhibitor
abl
inhibit
inflamm
also
reach
site
inflammatori
process
take
place
drug
deliveri
system
target
site
inflamm
protect
pla
inhibitor
vivo
degrad
detoxif
urgent
need
arachidonoyl
trifluoromethyl
keton
fig
aacocf
x
first
giva
cpla
inhibitor
report
although
potent
select
inhibitor
wide
use
studi
role
enzym
cell
anim
novel
nanoliposom
deliveri
system
inhibitor
aacocf
develop
melanoma
treatment
system
call
nanoatk
load
inhibitor
stabl
week
formul
decreas
toxicityen
administr
higher
dose
effect
kill
melanoma
cell
compar
free
aacocf
recent
new
gener
aa
analogu
develop
potenti
neurolog
agent
target
giva
cpla
among
compound
inhibitor
fig
exhibit
stronger
giva
cpla
inhibit
aacocf
inhibitor
found
giva
cpla
select
inhibitor
noncytotox
cell
brain
penetr
capabl
reduc
reactiv
oxygen
speci
ro
nitric
oxid
product
stimul
microgli
cell
giva
cpla
inhibitor
usual
suffer
high
lipophil
inhibitor
clogp
valu
higher
expect
present
favor
adm
properti
accord
lipinski
rule
five
clogp
valu
measur
hydrophob
repres
calcul
partit
coeffici
octanolwat
logarithm
scale
addit
molecular
weight
inhibitor
lower
accord
lipinski
rule
clogp
valu
calcul
use
chemdraw
togeth
molecular
weight
inhibitor
summar
tabl
obviou
none
present
clogp
valu
lower
furthermor
number
molecular
weight
higher
kokoto
denni
develop
past
potent
inhibitor
giva
cpla
demonstr
vivo
activ
continu
research
recent
report
new
reduc
lipophil
reduct
lipophil
vivo
activ
inhibitor
achiev
replac
long
aliphat
chain
chain
contain
aromat
ring
along
one
two
ether
oxygen
recent
kokoto
denni
develop
novel
class
highli
potent
giva
cpla
inhibitor
name
fig
contain
biphenyl
system
free
carboxyl
group
led
highli
potent
select
giva
cpla
vitro
inhibit
exhibit
x
valu
inhibitor
first
exampl
highli
potent
giva
cpla
inhibitor
present
clogp
valu
lower
clogp
valu
macrophag
treatment
potent
inhibitor
result
decreas
klaelicit
prostaglandin
product
apart
synthet
smallmolecul
natur
product
found
inhibit
giva
cpla
enzym
report
play
import
role
rosno
signal
microgli
activ
lipoxygenas
pathway
botan
polyphenol
quercetin
fig
honokiol
fig
effect
inhibit
lpsinduc
product
phosphoryl
giva
cpla
indic
potenti
use
botan
polyphenol
amelior
neurotox
effect
distinct
featur
mani
isoform
belong
group
vi
ipla
fact
calciumindepend
show
specif
aa
widespread
pla
throughout
human
tissu
first
wide
describ
member
famili
gvia
ipla
also
known
ipla
purifi
macrophag
also
possess
lysophospholipas
transacylas
acylcoa
thioesteras
activ
accord
homolog
model
sequenc
align
lipid
hydrolysi
execut
serasp
catalyt
dyad
sequenc
consist
linker
region
seven
ankyrin
repeat
catalyt
domain
recent
crystal
structur
gvia
ipla
reveal
protein
form
stabl
dimer
mediat
catalyt
domain
activ
site
close
proxim
posit
cooper
activ
intern
transacyl
activ
site
dimer
wide
open
provid
suffici
space
phospholipid
access
catalyt
center
ankyrin
repeat
domain
orient
toward
membranebind
interfac
interact
membran
protein
structur
gvia
ipla
monom
pdb
id
present
fig
miss
loop
fill
model
residu
activ
site
repres
ball
yellow
c
atom
red
atom
blue
n
atom
white
h
atom
recent
review
articl
ramanadham
et
al
discuss
detail
increas
decreas
express
ipla
may
affect
metabol
state
cn
function
cardiovascular
perform
cell
surviv
sinc
dysregul
ipla
may
play
critic
role
develop
mani
diseas
diabet
barth
syndrom
ovarian
cancer
ischemia
multipl
sclerosi
research
discoveri
potent
smallmolecul
inhibitor
therefor
consid
crucial
polyfluoroketon
constitut
import
class
potent
select
smallmolecul
gvia
ipla
inhibitor
use
studi
role
enzym
ex
vivo
vivo
particular
autoimmun
diseas
fig
present
x
valu
caus
strong
reduct
clinic
sever
progress
experiment
autoimmun
encephalomyel
anim
model
multipl
sclerosi
showcas
gvia
ipla
play
keyrol
onset
progress
diseas
fig
found
seven
time
potent
inhibitor
gvia
ipla
x
valu
time
potent
gvia
ipla
giva
cpla
gv
spla
respect
fig
even
potent
x
valu
revers
inhibitor
select
ipla
gvia
ipla
ipla
gvib
ipla
inhibit
serin
proteas
cytotox
inhibit
apoptosi
investig
impact
autoimmun
diabet
develop
administr
spontan
diabetespron
nonobes
diabet
nod
mice
found
significantli
decreas
incid
diabet
associ
reduc
insul
improv
glucos
homeostasi
higher
circul
insulin
preserv
area
moreov
reduc
tumor
necrosi
factor
alpha
product
tcell
antibodi
bcell
suggest
modul
immun
cell
respons
ipla
gvia
ipla
deriv
product
adopt
transfer
diabet
tcell
immunodefici
nondiabetogen
nodscid
mice
moder
pretreat
product
tcell
reduc
inhibitor
cyclooxygenas
cox
taken
togeth
observ
suggest
gvia
ipla
activ
promot
immun
respons
gvia
ipla
inhibit
may
benefici
amelior
diabet
also
use
along
inhibitor
role
three
differ
pla
type
spontan
progesteron
induc
acrosom
reaction
ar
could
studi
specif
use
giva
cpla
inhibitor
spla
group
x
inhibitor
bel
gvia
ipla
inhibitor
accord
result
gvia
ipla
crucial
spontan
ar
gvia
ipla
gx
spla
involv
ar
giva
cpla
dispens
type
moreov
progesteroneinduc
ar
found
long
last
process
spread
min
mous
kinet
analys
suggest
presenc
differ
sperm
subpopul
use
distinct
pla
pathway
achiev
ar
low
physiolog
concentr
sperm
undergo
earli
ar
min
reli
gvia
ipla
wherea
sperm
undergo
late
ar
min
reli
gx
spla
role
pla
ar
seem
depend
concentr
pla
key
actor
low
physiolog
concentr
higher
one
giva
cpla
gvia
ipla
studi
substrat
specif
inflammatori
activ
macrophag
zymosan
use
select
inhibitor
specif
giva
cpla
inhibitor
pyrrophenon
fig
gvia
ipla
inhibitor
fig
data
show
two
enzym
act
differ
phospholipid
pool
unlik
giva
cpla
gvia
ipla
particip
aa
releas
show
specif
cholin
glycerophospholipid
pc
speci
contain
palmit
acid
posit
gener
lysopc
lpc
major
acceptor
aa
incorpor
back
phospholipid
molecular
dock
calcul
md
simul
employ
structureact
relationship
sar
gvia
ipla
previous
synthes
inhibitor
could
establish
base
sar
model
new
compound
synthes
test
vitro
inhibitori
activ
giva
cpla
gv
spla
gvia
ipla
among
thioether
fluoroketon
compound
fig
thioether
compound
fig
potent
inhibit
gvia
ipla
quit
select
rel
giva
cpla
gv
spla
linear
aliphat
betasubstitut
trifluoromethyl
keton
test
human
gvia
ipla
giva
cpla
gv
spla
betathiotrifluoromethyl
keton
fig
found
highli
potent
inhibitor
gvia
ipla
x
valu
mol
fraction
ic
nm
show
signific
inhibit
toward
giva
cpla
gv
spla
addit
combin
hydrogen
deuterium
exchang
mass
spectrometri
dxm
computeraid
design
techniqu
led
enzymeinhibitor
complex
disclos
bind
mode
fig
bind
site
enzym
new
base
dipeptid
pseudodipeptid
synthes
studi
vitro
inhibitori
activ
human
gvia
ipla
well
select
pla
type
compound
fig
base
nlegabaobu
present
signific
inhibit
gvia
ipla
x
well
select
giva
cpla
gv
spla
bromoenol
lacton
fig
bel
irrevers
coval
inhibitor
gvia
ipla
exhibit
select
ipla
cpla
spla
year
bel
use
discern
involv
gvia
ipla
biolog
process
cellular
level
well
vivo
howev
sever
featur
bel
decreas
feasibl
cell
vivo
use
irrevers
inhibit
ipla
b
inactiv
serin
proteas
c
high
toxic
due
interact
cystein
report
ipla
ipla
express
activ
murin
cell
osteoblast
phenotyp
inhibit
bel
result
initi
increas
pge
format
due
ipla
independ
aa
accumul
follow
decreas
higher
bel
concentr
moreov
bel
seem
react
intracellular
cystein
glutathion
lead
glutathion
deplet
respons
decreas
pge
product
find
suggest
bel
must
use
caution
cellular
environ
sinc
data
present
resembl
condit
extrem
oxid
stress
secret
pla
first
type
pla
enzym
identifi
mammal
constitut
largest
famili
contain
catalyt
activ
isoform
ib
iia
iic
iid
iie
iif
iii
v
x
xiia
one
inact
isoform
xiib
differ
sourc
structur
function
typic
small
protein
kda
requir
ca
mm
concentr
catalyt
activ
util
asphi
dyad
activ
site
stabil
six
common
disulfid
bond
one
two
variabl
addit
one
individu
member
spla
exhibit
uniqu
tissu
cellular
distribut
enzymat
properti
suggest
distinct
biolog
role
act
either
catalyz
reaction
enzym
bind
receptor
henc
involv
activ
sever
biolog
pathway
maintain
spla
homeostasi
appear
critic
sever
physiolog
function
upregul
downregul
express
spla
isoform
relat
patholog
condit
atherosclerosi
immun
disord
cancer
summar
sever
review
articl
result
varieti
synthet
inhibitor
target
spla
develop
known
spla
inhibitor
indolebas
varespladib
fig
oral
bioavail
prodrug
varespladib
methyl
fig
enter
clinic
trial
inflammatori
diseas
eg
sepsi
rheumatoid
arthriti
acut
coronari
syndrom
fail
demonstr
poor
efficaci
recent
world
health
organ
ad
snakebit
envenom
prioriti
list
neglect
tropic
diseas
ntd
estim
fatal
snakebit
occur
victim
reach
hospit
antivenom
treatment
thu
small
molecul
therapeut
seem
attract
tool
initi
treatment
snakebit
prehospit
environ
adjunct
antivenom
therapi
varespladib
varespladib
methyl
shown
highlevel
spla
inhibit
nanoand
picomolar
concentr
medic
import
snake
venom
use
chromogen
assay
vivo
proofofconcept
studi
varespladib
strike
surviv
benefit
lethal
dose
micruru
fulviu
vipera
beru
venom
suppress
venominduc
spla
activ
rat
challeng
lethal
dose
fulviu
venom
inhibitori
potenti
varespladib
snake
envenom
also
evalu
anoth
research
group
treatment
varespladib
show
signific
inhibitori
effect
snake
venom
pla
estim
ic
vitro
ed
vivo
deinagkistrodon
acutu
ic
ed
agkistrodon
hali
ic
ed
g
anim
model
sever
hemorrhag
toxic
acutu
hali
venom
almost
fulli
inhibit
administr
moreov
sign
edema
gastrocnemiu
muscl
remark
attenu
administr
varespladib
reduc
loss
myonecrosi
desmin
serum
level
creatin
kinas
lactat
dehydrogenas
isoenzym
aspart
transaminas
alanin
transaminas
downregul
treatment
varespladib
indic
protect
viscera
injuri
effort
combin
pla
inhibitori
activ
indol
isoxazol
seri
indol
contain
isoxazol
deriv
studi
spla
inhibitor
among
compound
fig
show
spla
inhibitori
activ
ic
valu
vitro
test
group
rat
use
carrageenan
model
paw
volum
fig
show
edema
inhibit
h
h
respect
studi
demonstr
fig
show
vitro
antiprolif
activ
test
breast
prostat
cancer
cell
mtt
assay
astra
zeneca
develop
seri
biphenyl
deriv
spla
inhibitor
fig
inhibit
giia
gv
gx
spla
ic
valu
nm
respect
demonstr
high
plasma
spla
inhibit
ic
nm
vivo
dose
mg
oral
administ
cynomolgu
monkey
gener
concentrationdepend
inhibit
spla
activ
plasma
ic
nm
incub
cell
fig
inhibit
spla
activ
ic
nm
suppress
product
giia
spla
ic
nm
addit
fig
show
spla
inhibit
ic
nm
atherosclerot
plaqu
homogen
obtain
carotid
endarterectomi
coronari
arteri
diseas
patient
exhibit
excel
preclin
pharmacokinet
properti
across
differ
anim
speci
minim
safeti
risk
inhibitor
fig
select
clinic
candid
treatment
coronari
arteri
diseas
sinc
inhibitor
synthes
evalu
inhibitori
activ
variou
pla
type
continu
research
guid
molecular
dock
simul
led
deriv
fig
long
chain
base
valin
compound
fig
exhibit
high
potenc
inhibit
giia
spla
ic
nm
nm
human
mous
giia
spla
respect
inhibitor
proven
ten
time
select
giia
gv
spla
exhibit
appreci
inhibit
human
mous
spla
enzym
addit
inhibitor
fig
well
spla
inhibitor
present
signific
suppress
pge
releas
rat
renal
mesangi
cell
indic
spla
play
predomin
role
product
pge
quinoxalinon
deriv
dual
activ
biochem
unrel
enzym
mutual
involv
diabet
complic
present
studi
compound
show
low
micromolar
ic
valu
differ
spla
isozym
ic
satisfactori
ic
valu
ic
pancreat
instanc
compound
fig
inhibit
human
giia
human
gv
human
gx
human
gxiia
spla
ic
valu
respect
well
ic
unconjug
bilirubin
ucb
endogen
antioxid
previous
report
giia
spla
inhibitor
chemic
modif
led
hydrophob
deriv
evalu
inhibitori
activ
aa
cascad
enzym
dimethyl
ester
bilirubin
inhibit
giia
spla
activ
concentr
depend
manner
ic
valu
fold
lower
compar
ucb
vivo
fig
reduc
giia
spla
induc
edema
dose
depend
manner
compound
fig
also
inhibit
peroxidas
activ
concentr
depend
manner
ic
valu
respect
furthermor
fig
inhibit
aa
induc
platelet
aggreg
well
dose
depend
decreas
carrageenan
induc
mous
paw
edema
celastrol
fig
quinin
methid
triterpen
found
modul
inflamm
inhibit
catalyt
activ
mediat
aa
pathway
briefli
celastrol
inhibit
giia
spla
ic
activ
ic
concentrationdepend
manner
peroxidas
activ
ic
vitro
addit
inhibit
carrageenaninduc
edema
giia
spla
induc
edema
mice
coinject
differ
concentr
celastrol
human
giia
spla
hind
paw
mice
decreas
edema
ratio
dosedepend
manner
concentr
edema
complet
inhibit
celastrol
also
inhibit
lpsstimul
product
pge
human
neutrophil
exhibit
strong
antioxid
activ
variou
natur
product
claim
spla
inhibitor
maslin
acid
natur
pentacycl
triterpenoid
prove
interact
directli
human
giia
spla
inhibit
enzym
activ
concentrationdepend
manner
bind
calcium
bind
phospholipid
interfaci
site
maslin
acid
also
inhibit
human
giia
spla
induc
cell
differenti
migrat
sulforaphan
fig
sfn
natur
isothiocyan
present
crucifer
veget
examin
effect
express
activ
giia
spla
vitro
vivo
first
effect
sfn
express
activ
giia
spla
induc
lp
human
umbil
vein
endotheli
cell
huvec
determin
posttreat
sfn
mm
potent
inhibit
express
activ
giia
spla
vivo
cecal
ligat
punctur
clp
model
sepsi
posttreat
sfn
markedli
reduc
giia
spla
express
lpsinject
clpinduc
sepsi
mice
sfn
also
suppress
activ
giva
cpla
lp
phospholipas
belong
group
vii
group
viii
catalyz
hydrolysi
acetyl
group
posit
paf
potent
phospholipid
mediat
play
major
role
inflamm
therefor
name
paf
acetylhydrolas
pafah
gviia
pla
associ
lowand
highdens
lipoprotein
ldl
hdl
human
plasma
led
name
lipoproteinassoci
pla
lppla
lppla
calcium
independ
secret
extracellularli
enzym
kda
use
catalyt
triad
serhi
asp
lppla
show
broad
substrat
specif
apart
paf
also
hydrolyz
phosphatidylcholin
shortchain
residu
well
oxid
phospholipid
clone
human
plasma
shown
antiinflammatori
activ
vivo
howev
subsequ
clinic
studi
lppla
level
patient
establish
enzym
definit
marker
coronari
heart
diseas
recent
reagent
measur
lppla
activ
receiv
fda
approv
elev
level
lppla
associ
coronari
heart
diseas
stroke
thu
research
crucial
develop
new
inhibitor
lppla
darapladib
fig
potent
select
inhibitor
lppla
ic
nm
recombin
human
lppla
dnpg
assay
develop
glaxosmithklin
undergon
two
phase
trial
cardiovascular
diseas
discontinu
failur
reduc
risk
major
coronari
event
recent
darapladib
found
reduc
elev
lppla
rho
kinas
activ
cardiomyocyt
apoptosi
atherosclerosi
lead
cardiovascular
protect
vivo
rat
type
diabet
mellitu
model
darapladib
proven
reduc
inflamm
decreas
vascular
cell
adhes
intercellular
adhes
aorta
express
earli
stage
atherosclerosi
improv
insulin
resist
occur
metabol
disord
moreov
investig
effect
chronic
diabet
mellitu
hypercholesterolaemia
pig
retina
reveal
increas
permeabl
bloodretina
barrier
brb
coupl
alter
retin
architectur
includ
leak
plasma
compon
retina
select
immunoglobulin
g
bind
neuron
ganglion
cell
layer
thin
retin
layer
due
cell
loss
increas
glial
fibrillari
acid
protein
express
cell
curtail
treatment
darapladib
recent
crystal
structur
human
lppla
bound
darapladib
inhibitor
fig
ic
fairli
open
larg
rel
hydrophob
rigid
bind
pocket
key
interact
inhibitor
lppla
reveal
structur
lppla
prove
rigid
bind
darapladib
fig
lppla
chang
overal
conform
protein
furthermor
isotherm
titrat
calorimetri
experi
reveal
bind
two
inhibitor
lppla
driven
enthalp
effect
influenc
entropi
bind
neg
glaxosmithklin
also
introduc
rilapladib
fig
fig
enter
clinic
trial
potenti
treatment
alzheim
diseas
ad
rilapladib
complet
phase
studi
evalu
effect
ad
demonstr
improv
cognit
outcom
chang
number
mechanismand
diseaserel
biomark
suggest
rilapladib
inhibit
lppla
may
potenti
slow
progress
ad
alter
underli
patholog
subpopul
ad
patient
neuroimag
evid
cerebrovascular
diseas
evalu
safeti
toler
pharmacokinet
pharmacodynam
healthi
volunt
phase
clinic
trial
compound
gener
well
toler
reason
pkpd
profil
order
refin
therapeut
dose
predict
confirm
brain
penetr
radiolabel
form
inhibitor
f
manufactur
use
pet
biodistribut
phase
studi
accord
result
abl
cross
blood
brain
barrier
enter
human
brain
exploratori
analysi
data
indic
dose
mg
twice
daili
would
suffici
brain
lppla
anoth
studi
investig
whether
lppla
lysophosphatidylcholin
lpc
involv
brb
damag
diabet
retinopathi
use
analog
darapladib
system
lppla
inhibit
use
fig
mgkg
ip
effect
suppress
brb
breakdown
streptozotocindiabet
brown
norway
rat
inhibitori
effect
compar
intravitr
vascular
endotheli
growth
factor
vegf
neutral
protect
brb
dysfunct
addit
target
inhibit
simultan
mechanist
studi
primari
brain
retin
microvascular
endotheli
cell
well
occlud
rat
pial
microvessel
show
lumin
ablumin
lpc
potent
induc
permeabl
requir
signal
vegf
receptor
result
suggest
lppla
could
efficaci
therapeut
target
diabet
macular
edema
dme
either
alon
combin
antivegf
therapeut
anoth
seri
pyrimidon
deriv
test
lppla
inhibitori
activ
effect
dme
compound
fig
demonstr
decent
pharmacokinet
profil
robust
inhibitori
potenc
lppla
male
spraguedawley
sd
rat
deriv
present
ic
valu
nm
rat
plasma
recombin
human
lppla
respect
moreov
fig
significantli
inhibit
retin
thicken
streptozotocininduc
diabet
sd
rat
model
dme
oral
dose
week
combin
fragment
screen
crystal
structur
determin
virtual
screen
medicin
chemistri
led
identif
novel
sulfonamid
lppla
inhibitor
compound
exhibit
high
inhibitori
activ
ic
nm
good
stabil
well
good
permeabl
vitro
addit
inhibitor
fig
show
favor
oral
bioavail
male
sd
rat
maintain
inhibitori
activ
h
oral
administr
superior
darapladib
xray
fragment
screen
conduct
order
identifi
lppla
inhibitor
make
direct
interact
catalyt
residu
enzym
screen
led
identif
numer
fragment
hit
effect
map
activ
site
enzym
occupi
bind
surfac
similar
defin
darapladib
howev
subset
fragment
hit
reveal
bind
novel
pocket
approxim
oxyanion
hole
form
rotat
side
chain
instanc
compound
fig
fig
exhibit
low
ic
valu
molecular
weight
da
clogp
valu
respect
addit
compar
human
plasma
protein
bind
artifici
membran
permeabl
darapladib
final
work
halt
neither
thiazol
fig
pyrazol
fig
possess
pk
properti
consist
oncedaili
dose
human
nonetheless
success
fragment
base
drug
discoveri
identifi
ligand
effici
compound
vastli
improv
physicochem
properti
demonstr
base
fragmentbas
approach
lactam
inhibitor
lppla
develop
compound
fig
bear
sulfon
moieti
present
ic
valu
nm
whole
human
plasma
assay
inhibitori
potenc
similar
darapladib
howev
fig
significantli
lower
mw
less
lipophil
darapladib
moreov
inhibitor
fig
promis
pharmacokinet
properti
found
bind
oxyanion
hole
enzym
comput
studi
contribut
better
understand
enzymesubstr
enzymeinhibitor
interact
also
constitut
power
tool
discov
novel
inhibitor
applic
ration
drug
design
develop
pla
inhibitor
review
past
combin
comput
experiment
studi
proven
use
defin
inhibitor
bind
site
facilit
gener
improv
enzym
inhibitor
combin
md
simul
dxm
help
understand
pyrrophenon
inhibitor
interact
giva
cpla
fluoroketon
interact
gvia
ipla
comput
studi
also
employ
simul
interact
pla
substrat
cell
membran
membraneassoci
member
bind
mode
phospholipid
activ
site
giva
cpla
gvia
ipla
explor
use
md
simul
driven
dxm
data
studi
highlight
import
interact
proteinmembran
substrat
bind
catalyt
mechan
sinc
xray
structur
avail
time
homolog
model
gvia
ipla
creat
result
show
polar
head
substrat
papc
occupi
hydrophil
area
close
catalyt
center
phosphat
group
creat
hydrogen
bond
giva
cpla
gvia
ipla
carbonyl
group
posit
locat
near
catalyt
giva
cpla
gvia
ipla
aliphat
chain
fatti
acid
accommod
hydrophob
area
channel
protein
fig
continu
work
mouchli
et
al
explor
substrat
specif
lipidom
md
simul
discov
uniqu
hydrophob
area
bind
site
accommod
cleav
fatti
acid
thu
drive
substrat
specif
base
structur
analysi
md
simul
identifi
optim
phospholipid
bind
mode
case
giva
cpla
could
explain
substrat
specif
differ
gvia
ipla
gv
spla
comput
studi
organ
synthesi
vitro
assay
led
develop
potent
select
gvia
ipla
inhibitor
homolog
model
gvia
ipla
use
bind
pocket
defin
residu
bind
mode
trifluoromethyl
keton
pentafluoroethyl
keton
gener
ifd
induc
fit
dock
calcul
pose
subject
md
simul
namd
ns
accord
result
fig
although
carbonyl
group
compound
interact
oxyanion
hole
creat
interact
catalyt
also
interact
fluorin
atom
creat
seem
critic
bind
interestingli
methoxyphenyl
group
inhibitor
naphthalen
group
inhibitor
locat
entranc
bind
pocket
initi
pose
move
hydrophob
region
simul
bind
mode
fluoroketon
inhibitor
giva
cpla
also
studi
result
show
fluoroketon
function
group
use
construct
inhibitor
exhibit
select
either
gvia
ipla
giva
cpla
size
hydrophob
chain
critic
activ
select
shortchain
compound
tend
select
inhibit
gvia
ipla
longchain
compound
also
inhibit
giva
cpla
studi
togeth
studi
report
mouchli
et
al
indic
import
presenc
sulfur
atom
activ
carbonyl
group
fluoroketon
bind
mode
novel
thioether
deriv
gvia
ipla
also
studi
carbonyl
group
interact
oxyanion
hole
interact
via
hydrogen
bond
oxadiazol
ring
benefici
insert
sulfur
atom
depict
higher
affin
accord
md
simul
due
interact
residu
fig
recent
librari
small
molecul
contain
function
gener
inhibitor
deriv
biphenyl
group
free
carboxyl
group
present
high
inhibitori
activ
giva
cpla
accord
bind
mode
describ
paper
carboxyl
group
molecul
interact
moieti
interact
oxyanion
hole
via
hydrogen
bond
fig
structur
modif
known
spla
inhibitor
use
comput
tool
report
design
new
deriv
improv
potenc
dock
calcul
evalu
deriv
cocrystal
inhibitor
suggest
synthesi
new
deriv
reproduc
key
interact
residu
bind
pocket
present
lower
bind
energi
addit
mouchli
et
al
report
use
threedimension
quantit
structureact
relationship
model
design
evalu
new
indol
deriv
spla
construct
model
base
set
indol
inhibitor
gener
new
indol
deriv
reproduc
key
interact
bind
mode
inhibitor
giia
spla
studi
use
gold
molecular
dock
calcul
md
simul
amber
led
develop
potent
giia
spla
inhibitor
fig
dock
calcul
also
employ
simul
interact
giva
cpla
inhibitor
complex
inhibitor
interact
calcium
ion
giia
spla
via
carboxyl
group
group
amid
function
md
simul
complex
two
hydrogen
bond
form
amid
group
residu
result
stabl
bind
enzym
assay
activ
pla
challeng
although
enzym
watersolubl
act
phospholipid
substrat
aggreg
aqueou
solut
form
micel
vesicl
liposom
inhibit
pla
type
compar
one
must
note
particular
assay
condit
aggreg
form
substrat
use
almost
twenti
year
ago
groupspecif
radiolabelbas
assay
abl
distinguish
four
major
type
mammalian
pla
develop
purpos
subchapt
highlight
recent
report
assay
recent
novel
mass
spectrometricbas
highthroughput
assay
wellplat
assay
toward
natur
synthet
membran
phospholipid
mix
micel
nonion
surfact
report
lipidomicsbas
hplcm
assay
hilic
column
multipl
reaction
monitor
mrm
use
target
quantif
assay
compon
includ
surfact
octaethylen
glycol
monododecyl
ether
free
fatti
acid
aa
phospholipid
papc
lysophospholipid
lpc
intern
standard
lpc
aa
detect
neg
electrospray
ioniz
esi
mode
lysophospholipid
phospholipid
surfact
posit
esi
mode
unexpect
head
group
acyl
chain
specif
three
major
pla
type
discov
studi
allow
detail
understand
prefer
giva
cpla
cleavag
proinflammatori
aa
indic
prefer
giva
ipla
cleavag
linol
acid
prefer
gv
spla
linol
acid
satur
fatti
acid
phosphatidylglycerol
barbour
ramanadham
report
detail
procedur
measur
gvia
ipla
specif
activ
cell
line
tissu
prepar
use
simpl
radiolabelbas
assay
evalu
impact
smallmolecul
inhibitor
restingand
diseasest
gvia
ipla
activ
assay
provid
rapid
select
quantifi
measur
gvia
ipla
specif
activ
without
requir
purif
enzym
although
papc
common
choic
radiolabel
substrat
dppc
plpc
z
h
pc
also
suitabl
plasmalogen
phospholipid
pc
contain
vinyl
ether
linkag
posit
extrem
favor
substrat
gvia
ipla
fluorometr
highthroughput
screen
assay
spla
use
phospholipid
vesicl
develop
use
identifi
human
giii
spla
inhibitor
librari
small
molecul
substrat
present
phospholipid
vesicl
matrix
close
resembl
natur
substrat
human
giii
spla
oppos
phospholipiddeterg
mix
micel
phospholipid
analogu
contain
bodipi
fluorophor
dispers
minor
compon
vesicl
nonfluoresc
phospholipid
use
substrat
increas
fluoresc
observ
enzym
act
liber
free
fatti
acid
phospholipid
reduct
quench
fluorophor
occur
assay
use
optic
detect
plate
format
colorimetr
assay
use
paf
analog
phosphatidylcholin
substrat
chemic
lppla
activ
assay
commonli
use
lppla
activ
assay
current
clinic
set
colorimetr
assay
prove
accur
robust
accept
linear
wide
rang
activ
level
allow
adopt
lppla
activ
clinic
practic
recent
novel
enzymat
method
assay
lppla
serum
develop
lppla
activ
assay
use
phosphocholin
rac
paf
substrat
hydrolyz
lppla
produc
lysopaf
lysopaf
hydrolyz
lysoplasmalogenspecif
phospholipas
lysophospholipas
gener
cholin
detect
cholin
oxidas
regress
analysi
lppla
activ
measur
enzymat
lppla
activ
assay
vs
two
chemic
lppla
activ
assay
ie
lppla
fs
test
elisa
gave
follow
correl
coeffici
respect
n
sever
smallmolecul
inhibitor
spla
cpla
lppla
studi
clinic
trial
safeti
efficaci
human
advanc
clinic
trial
pla
inhibitor
togeth
diseas
indic
summar
tabl
varespladib
spla
inhibitor
first
pla
inhibitor
advanc
clinic
trial
intravenouslyadminist
therapi
sepsisinduc
system
inflammatori
respons
syndrom
although
end
phase
studi
found
accept
safeti
profil
patient
sever
sepsi
trial
termin
phase
ii
studi
show
poor
efficaci
doubleblind
placebocontrol
clinic
trial
varespladib
methyl
fail
show
efficaci
treatment
rheumatoid
arthriti
later
varespladib
methyl
evalu
cardiovascular
diseas
franci
fewer
recurr
acut
coronari
event
nearterm
cardiovascular
inflamm
suppress
studi
demonstr
treatment
varespladib
methyl
reduc
concentr
ldlc
hscrp
spla
ac
patient
treat
evidencebas
therapi
inclus
highdos
atorvastatin
vascular
inflamm
suppress
treat
acut
coronari
syndrom
week
clinic
trial
evalu
safeti
efficaci
week
treatment
varespladib
methyl
morbid
mortal
ad
atorvastatin
standard
care
subject
ac
howev
studi
termin
due
lack
efficaci
giripladib
indolebas
giva
cpla
advanc
phase
ii
clinic
trial
osteoarthr
trial
termin
due
gastrointestin
event
random
doubleblind
placebo
control
studi
determin
safeti
toler
pharmacokinet
efficaci
topic
anoth
indolebas
giva
cpla
inhibitor
ointment
adult
healthi
volunt
patient
moder
sever
atop
dermat
progress
result
inform
yet
publicli
avail
darapladib
potent
select
lppla
inhibitor
undergon
two
phase
iii
trial
cardiovascular
diseas
fail
reduc
risk
major
coronari
event
recent
clinic
trial
rilapladib
anoth
lppla
inhibitor
complet
demonstr
improv
cognit
outcom
chang
number
mechanismand
diseaserel
biomark
suggest
inhibit
lppla
may
potenti
slow
progress
ad
addit
lppla
inhibitor
evalu
safeti
toler
pharmacokinet
pharmacodynam
healthi
volunt
phase
clinic
trial
overal
although
sever
smallmolecul
pla
inhibitor
evalu
clinic
trial
none
reach
market
yet
trial
spla
inhibitor
varespladib
varespladib
methyl
fail
exhibit
expect
vivo
efficaci
cpla
inhibitor
giripladib
caus
undesir
side
effect
recent
result
show
highlevel
spla
inhibit
varespladib
varespladib
methyl
medic
import
snake
venom
suggest
spla
inhibitor
may
find
use
initi
treatment
snakebit
prehospit
environ
case
cpla
inhibitor
previous
notic
high
lipophil
known
cpla
inhibitor
seriou
drawback
thu
seem
inhibitor
may
suitabl
topic
use
exampl
treatment
dermat
rather
system
use
fortun
potent
cpla
inhibitor
clogp
valu
lower
exampl
recent
discov
lppla
enzym
failur
potent
lppla
inhibitor
darapladib
reduc
risk
major
coronari
event
demonstr
stabil
solidtimi
phase
iii
studi
indic
enzym
may
biomark
vascular
inflamm
rather
target
pharmaceut
treatment
benefici
effect
conclus
although
pharmaceut
compani
academ
institut
devot
huge
effort
develop
pla
inhibitor
seem
still
fundament
issu
connect
structur
cellular
function
involv
pla
type
particular
diseas
clearli
understood
exampl
recent
combin
lcm
lipidom
md
simul
reveal
surpris
previous
unrecogn
substrat
specif
spla
ipla
expect
advanc
analyt
lipidom
approach
comput
method
may
contribut
increas
knowledg
pla
superfamili
enzym
addit
recent
solv
crystal
structur
gvia
ipla
may
help
design
novel
inhibitor
enzym
classic
medicin
chemistri
approach
includ
organ
synthesi
structureact
relationship
studi
well
modern
approach
employ
function
lipidom
computeraid
drug
design
may
provid
new
chemic
entiti
potenti
novel
pharmaceut
agent
